BR112012018766A2 - métodos de tratamento de doenças autoimunes com antagonistas de dll4. - Google Patents

métodos de tratamento de doenças autoimunes com antagonistas de dll4.

Info

Publication number
BR112012018766A2
BR112012018766A2 BR112012018766A BR112012018766A BR112012018766A2 BR 112012018766 A2 BR112012018766 A2 BR 112012018766A2 BR 112012018766 A BR112012018766 A BR 112012018766A BR 112012018766 A BR112012018766 A BR 112012018766A BR 112012018766 A2 BR112012018766 A2 BR 112012018766A2
Authority
BR
Brazil
Prior art keywords
methods
dii4
diseases
disorders
autoimmune diseases
Prior art date
Application number
BR112012018766A
Other languages
English (en)
Inventor
Dimitris Skokos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BR112012018766A2 publication Critical patent/BR112012018766A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

patente de invenção: métodos de tratamento de doenças autoimunes com antagonistas de dll4. a presente invenção refere-se a métodos de tratamento de uma doença ou distúrbios, onde aumento do número de célula t reguladora (treg) é benéfico, através da administração a um indivíduo sofrendo de tal doença ou distúrbio de uma quantidade terapeuticamente eficaz de antagonista de dii4 que bloqueiam os cursos de sinal de dii4-notch, desta maneira aumentando o número de treg. doenças ou distúrbios tratáveis através dos métodos da invenção incluem doenças ou distúrbios autoimunes, tais como esclerose múltipla (ms), diabetes e similar. antagonistas de dii4 adequados para a invenção incluem anticorpos ou fragmentos de anticorpo que se ligam especificamente a dii4 e bloqueiam as interações dii4-notch, o domínio extracelular d dii4, e similar. a invenção também refere-se a métodos de prevenção de uma ocorrência ou recorrência de tais doenças ou distúrbios em um indivíduo predisposto ou suscetível a desenvolvimento de tais doenças ou distúrbios. ainda, os métodos da invenção são úteis na prevenção ou tratamento de rejeições de transplante de órgão ou doença enxerto-versus-hospedeiro.
BR112012018766A 2010-01-29 2011-01-28 métodos de tratamento de doenças autoimunes com antagonistas de dll4. BR112012018766A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29980110P 2010-01-29 2010-01-29
US36168710P 2010-07-06 2010-07-06
US38869710P 2010-10-01 2010-10-01
PCT/US2011/022810 WO2011094465A1 (en) 2010-01-29 2011-01-28 Methods of treating autoimmune diseases with dll4 antagonists

Publications (1)

Publication Number Publication Date
BR112012018766A2 true BR112012018766A2 (pt) 2017-01-10

Family

ID=43925413

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112012018820A BR112012018820A8 (pt) 2010-01-29 2011-01-28 método de tratamento de diabetes com antagonistas de dll4
BR112012018766A BR112012018766A2 (pt) 2010-01-29 2011-01-28 métodos de tratamento de doenças autoimunes com antagonistas de dll4.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112012018820A BR112012018820A8 (pt) 2010-01-29 2011-01-28 método de tratamento de diabetes com antagonistas de dll4

Country Status (29)

Country Link
US (3) US8765125B2 (pt)
EP (2) EP2528946B1 (pt)
JP (2) JP5997613B2 (pt)
KR (2) KR101797918B1 (pt)
CN (2) CN102947336B (pt)
AR (1) AR080026A1 (pt)
AU (2) AU2011210771B2 (pt)
BR (2) BR112012018820A8 (pt)
CA (2) CA2787394C (pt)
CY (2) CY1118223T1 (pt)
DK (2) DK2528946T3 (pt)
ES (2) ES2609663T3 (pt)
HR (2) HRP20170130T1 (pt)
HU (2) HUE032985T2 (pt)
IL (2) IL220889A (pt)
JO (2) JO3183B1 (pt)
LT (2) LT2528946T (pt)
MX (2) MX343555B (pt)
MY (2) MY156353A (pt)
PL (2) PL2528945T3 (pt)
PT (2) PT2528945T (pt)
RS (2) RS55715B1 (pt)
RU (2) RU2587624C2 (pt)
SG (4) SG10201500404QA (pt)
SI (2) SI2528945T1 (pt)
SM (2) SMT201600412B (pt)
TW (2) TWI564019B (pt)
UY (1) UY33206A (pt)
WO (2) WO2011094467A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
CN102741288B (zh) 2009-08-29 2015-08-19 Abbvie公司 治疗用dll4结合蛋白
ES2700450T3 (es) 2009-10-16 2019-02-15 Oncomed Pharm Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
JO3183B1 (ar) 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
JP5964249B2 (ja) 2010-03-02 2016-08-03 アッヴィ・インコーポレイテッド 治療用ｄｌｌ４結合タンパク質
KR102091293B1 (ko) 2011-09-23 2020-03-20 온코메드 파마슈티칼스, 인크. Vegf/dll4 결합제 및 그의 용도
KR101535341B1 (ko) * 2012-07-02 2015-07-13 한화케미칼 주식회사 Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도
BR112015009961B1 (pt) 2012-11-01 2020-10-20 Abbvie Inc. proteína de ligação capaz de se ligar a dll4 e vegf, bem como composição que a compreende como composição que a compreende
AR093445A1 (es) * 2012-11-14 2015-06-10 Regeneron Pharma Metodos para tratar el cancer de ovario con antagonistas de dll4
EP3020731B1 (en) 2013-07-09 2019-06-12 ABLBio Novel dual-targeted protein specifically binding to dll4 and vegf, and use thereof
CN111239415B (zh) * 2013-10-17 2024-03-26 综合医院公司 鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物
US10413605B2 (en) * 2014-04-08 2019-09-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Combination therapy for the treatment of autoimmune diseases
EP3212233B1 (en) 2014-10-31 2020-06-24 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
US10716792B2 (en) 2018-11-29 2020-07-21 Gary Aaron Howard Neuroquiescence—a treatment for neurological and nervous system bioelectrical dysregulation associated with seizures of epilepsy
US11446262B2 (en) 2018-11-29 2022-09-20 Debora Zucco Sassi Yonezawa Siviglia Neuroquiescence—a treatment for neurodevelopmental and neurodegenerative bioelectrical dysregulation and demyelination
JPWO2022210802A1 (pt) * 2021-03-30 2022-10-06
WO2023159166A1 (en) * 2022-02-18 2023-08-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. Single-domain antibodies (nanobodies) targeting the notch ligand dll4 and methods of their use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
AU2003248558B8 (en) * 2002-05-21 2009-07-09 Gilead Sciences, Inc. Method of treating diabetes
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US20060134121A1 (en) * 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
ES2400666T5 (es) 2005-12-16 2016-03-10 Regeneron Pharmaceuticals, Inc. Uso terapéutico de un antagonista de DII4 y un inhibidor de VEGF para inhibir el crecimiento tumoral
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
AU2007319672B2 (en) * 2006-06-06 2011-06-30 Genentech, Inc. Anti-DLL4 antibodies and methods using same
TW200817435A (en) 2006-06-06 2008-04-16 Genentech Inc Compositions and methods for modulating vascular development
CA2660235C (en) 2006-08-07 2015-09-22 Regeneron Pharmaceuticals, Inc. Therapeutic methods for treating vascular eye disorders with dll4 antagonists
EP2066694B1 (en) 2006-09-29 2015-11-04 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
CN102741288B (zh) 2009-08-29 2015-08-19 Abbvie公司 治疗用dll4结合蛋白
JO3183B1 (ar) 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4

Also Published As

Publication number Publication date
IL220887A (en) 2017-07-31
TWI564019B (zh) 2017-01-01
RS55595B1 (sr) 2017-06-30
KR101832118B1 (ko) 2018-02-26
EP2528945B1 (en) 2016-10-26
AR080026A1 (es) 2012-03-07
CA2787615C (en) 2019-01-15
CN102947336A (zh) 2013-02-27
WO2011094467A2 (en) 2011-08-04
HRP20170249T1 (hr) 2017-04-07
CA2787394C (en) 2019-01-08
HRP20170130T1 (hr) 2017-03-24
EP2528945A2 (en) 2012-12-05
WO2011094467A3 (en) 2011-12-22
JO3183B1 (ar) 2018-03-08
PT2528946T (pt) 2016-12-14
WO2011094465A4 (en) 2011-09-22
US8889133B2 (en) 2014-11-18
CA2787615A1 (en) 2011-08-04
EP2528946B1 (en) 2016-11-16
SG182528A1 (en) 2012-08-30
PT2528945T (pt) 2016-12-14
UY33206A (es) 2011-08-31
PL2528945T3 (pl) 2017-02-28
AU2011210773A1 (en) 2012-08-23
BR112012018820A8 (pt) 2018-03-13
TW201136601A (en) 2011-11-01
PL2528946T3 (pl) 2017-04-28
US20110189176A1 (en) 2011-08-04
US20140255429A1 (en) 2014-09-11
ES2609663T3 (es) 2017-04-21
JP5997613B2 (ja) 2016-09-28
RU2012136817A (ru) 2014-03-10
SI2528945T1 (sl) 2017-01-31
RU2587620C2 (ru) 2016-06-20
JP5883801B2 (ja) 2016-03-15
HUE031432T2 (en) 2017-07-28
MY156353A (en) 2016-02-15
DK2528945T3 (en) 2017-02-06
HUE032985T2 (en) 2017-11-28
JP2013518123A (ja) 2013-05-20
CY1118551T1 (el) 2017-07-12
JO3242B1 (ar) 2018-03-08
IL220889A0 (en) 2012-09-24
RU2587624C2 (ru) 2016-06-20
MX343553B (es) 2016-11-10
AU2011210771B2 (en) 2015-12-10
MX343555B (es) 2016-11-10
CN102947336B (zh) 2015-12-02
AU2011210773B2 (en) 2015-11-19
US8765125B2 (en) 2014-07-01
RS55715B1 (sr) 2017-07-31
SG10201500416RA (en) 2015-04-29
SG10201500404QA (en) 2015-03-30
EP2528946A1 (en) 2012-12-05
ES2605430T3 (es) 2017-03-14
SI2528946T1 (sl) 2017-01-31
CN102884081A (zh) 2013-01-16
IL220889A (en) 2017-07-31
KR20130008017A (ko) 2013-01-21
SMT201600412B (it) 2017-01-10
MX2012008740A (es) 2012-08-31
CY1118223T1 (el) 2017-06-28
TW201615207A (zh) 2016-05-01
KR20120123745A (ko) 2012-11-09
TWI600433B (zh) 2017-10-01
AU2011210771A1 (en) 2012-08-23
SG182527A1 (en) 2012-08-30
JP2013518122A (ja) 2013-05-20
LT2528946T (lt) 2017-01-25
BR112012018820A2 (pt) 2017-01-10
LT2528945T (lt) 2017-01-25
KR101797918B1 (ko) 2017-11-15
US20110189200A1 (en) 2011-08-04
CA2787394A1 (en) 2011-08-04
DK2528946T3 (en) 2017-02-20
WO2011094465A1 (en) 2011-08-04
RU2012136816A (ru) 2014-03-10
SMT201700021B (it) 2017-03-08
MX2012008638A (es) 2012-12-05
MY156538A (en) 2016-02-26

Similar Documents

Publication Publication Date Title
BR112012018766A2 (pt) métodos de tratamento de doenças autoimunes com antagonistas de dll4.
AR072571A1 (es) Composiciones monovalentes para union a cd28 y procedimientos de uso
AR073459A1 (es) Composiciones de dominios variables de anticuerpos monovalentes para la union de cd28 y metodos de uso
BR112012022214A2 (pt) métodos e composições para tratar doença de degos
BR112013007314A2 (pt) anticorpos anti-cd48 e seus usos
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
BR112013026828A2 (pt) polipeptídeos de anticorpo que antagonizam cd40
GEP20146181B (en) Anti cxcr4 antibodies for treatment of hiv
BRPI1010587A2 (pt) métodos para aumentar adipócitos termogênicos
JO3097B1 (ar) الأجسام المضادة c-Met
UA114712C2 (uk) Моноклональне антитіло, яке імуноспецифічно зв'язується з людським psgl-1, та його застосування
BR112012015740A2 (pt) anticorpos de anti-flt3 e metodos de uso dos mesmos
BR112013001062A2 (pt) anticorpos humanizados que visam o domínio ec1 de caderina-11 e composições e métodos relacionados
EA201270591A1 (ru) ДВУЗАМЕЩЕННЫЕ ОКТАГИДРОПИРРОЛ[3,4-c]ПИРРОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ ОРЕКСИНОВЫХ РЕЦЕПТОРОВ
BR112012001984B8 (pt) anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica
BR112014015111A2 (pt) composições e processos para anticorpos que se direcionam ao fator p
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
BR112013031485A8 (pt) Anticorpo monoclonal isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, usos e método in vitro para bloqueio ou prevenção da ligação de p. aeruginosa a células epiteliais
BR112014003704A2 (pt) moduladores ror gama
WO2013013025A3 (en) Anti-cxcr4 antibodies and methods of use
EA201991704A3 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
EA201390874A1 (ru) Моноклональное антитело человека со специфичностью к белку e вируса денге серотипа 1 и его применение
BR112014008804A2 (pt) suportes derivados de tn3 específicos para cd40l e métodos de uso dos mesmos
EA201300137A1 (ru) Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний, связанных с нейродегенеративными зоболеваниями
TN2012000466A1 (en) Humanized anti cxcr4 antibodies for the treatment of cancer

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2551 DE 26-11-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]